Jump to contents

Researcher Information

last modified:2021/09/28

Associate Professor SUGA Yukio

Mail

Faculty, Affiliation

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Department of Clinical Pharmacy and Healthcare Sciences, Facluty of Pharmacy

College and School Educational Field


School of Pharmacy, College of Medical, Pharmaceutical and Health Sciences

Laboratory

Clinical Pharmacy and Healthcare Sciences TEL:076-265-2831

Academic Background

【Academic background(Doctoral/Master's Degree)】
Kanazawa University Doctor 200503 Completed
Kanazawa University Master 200003 Completed
【Academic background(Bachelor's Degree)】
Kitasato University 199803
【Degree】
doctor of philosophy in pharmaceutical science

Career

kanazawa univercity hospital(2000/04/01-2007/09/30)
kanazawa univercity(2007/10/01-2017/06/30)
kanazawa univercity(2017/07/01-)

Year & Month of Birth

Academic Society

the pharmaceutical society of japan
JSHPCS

japanese society of medical oncology
japan society of clinical oncology

the japanese society on thrombosis and hemostasis

Award

the japanese society on thrombosis and hemostasis
the japanese society on thrombosis and hemostasis

Specialities

Medical pharmacy

Speciality Keywords

Managment of cancer chemotherapy-induced advers events,Thrombosis

Research Themes

Surveillance and development of preventive method for chemotherapy-induced adverse drug reaction

clarification of pathology and search for the new treatment of disseminated intravascular coagulation

Books

Papers

  •  Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats. Yukio Suga,Kiyomichi Tashiro,Yukiko Staub,Shiori Komura,Shinya Yamada,Eriko Morishita,Hidesaku Asakura Thrombosis research 206 84 2021/08/19
  •  Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model Yukio Suga,Yoko Takahashi,Tsutomu Shimada,Shinya Yamada,Eriko Morishita,Hidesaku Asakura In Vivo 35 4 1999 2021/07
  •  Factors Associated with Self-reported Medication Adherence in Japanese Community-dwelling Elderly Individuals: The Nakajima Study. Natsuko Ishida,Yurina Tokumoto,Yukio Suga,Moeko Noguchi-Shinohara,Chiemi Abe,Sohshi Yuki-Nozaki,Ayaka Mori,Mai Horimoto,Koji Hayashi,Kazuo Iwasa,Masami Yokogawa,Mai Ishimiya,Hiroyuki Nakamura,Kiyonobu Komai,Ryo Matsushita,Junko Ishizaki,Masahito Yamada Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 141 5 751 2021/05/01
  •  Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats. Yukio Suga,Anna Kubo,Hideyuki Katsura,Yukiko Staub,Kiyomichi Tashiro,Shinya Yamada,Eriko Morishita,Hidesaku Asakura International journal of hematology 2021/04/27
  •  Initial Serum C-reactive Protein Level as a Predictor of Increasing Serum Vancomycin Concentration During Treatment. Kazuya Isoda,Junya Nakade,Yukio Suga,Arimi Fujita,Tsutomu Shimada,Yoshimichi Sai Therapeutic drug monitoring 2021/02/01

show all

  •  Sarcopenia may Influence the Prognosis in Advanced Thyroid Cancer Patients Treated With Molecular Targeted Therapy AKIHIRO NISHIYAMA,YUKIKO STAUB,YUKIO SUGA,MIKIYA FUJITA,AZUSA TANIMOTO,KOUSHIRO OHTSUBO,SEIJI YANO In Vivo 35 1 401 2021/01 
  •  Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma KO MISAKA,YUKIO SUGA,YUKIKO STAUB,ATSUMI TSUBATA,TSUTOMU SHIMADA,YOSHIMICHI SAI,RYO MATSUSHITA In Vivo 34 6 3459 2020/11/01 
  •  Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer YUSUKE SHIMURA,YUKIO SUGA,SHINGO ITAI,HIROAKI IWAMOTO,YUTA TAKEZAWA,HIROSHI YAEGASHI,KOUJI IZUMI,TSUTOMU SHIMADA,YOSHIMICHI SAI,RYO MATSUSHITA,ATSUSHI MIZOKAMI Anticancer Research 40 8 4291 2020/08 
  •  Detailed assessment and risk factor analysis of corticosteroid-induced psychiatric disorders in pediatric, adolescent, and young adult patients undergoing induction or consolidation therapy for hematologic malignancy Yukiko Staub,Yukio Suga,Yasuhiro Ikawa,Kiyotaka Tsubouchi,Mikie Hashimoto,Atsufumi Kawagishi,Tsutomu Shimada,Yoshimichi Sai,Katsuji Nishimura,Ryo Matsushita Journal of Oncology Pharmacy Practice 26 5 1041 2020/07 
  •  Examination of Aggregate Formation upon Simultaneous Dissolution of Methacrylic Acid Copolymer LD Enteric Coating Agent, Pharmaceutical Additives, and Zwitterionic Ingredients Nakagawa Y,Suzuki T,Suga Y,Shimada T,Sai Y Biol. Pharm. Bull. 43 4 682 2020/04
  •  A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy Junko Ishizaki,Chihiro Nakano,Kana Kitagawa,Yukio Suga,Yoshimichi Sai Annals of Pharmacotherapy 54 1 29 2020/01 
  •  Pharmacokinetics and tissue distribution of 3,4‐diaminopyridine in rats Natsuko Ishida,Yuya Kondo,Yuri Chikano,Erina Kobayashi‐Nakade,Yukio Suga,Junko Ishizaki,Kiyonobu Komai,Ryo Matsushita Biopharmaceutics & Drug Disposition 40 8 294 2019/09 
  •  A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan Mayako Uchida,Shinya Suzuki,Hideki Sugawara,Yukio Suga,Hideya Kokubun,Yoshihiro Uesawa,Takayuki Nakagawa,Hisamitsu Takase Journal of Pharmaceutical Health Care and Sciences 5 1 2019/12 
  •  Clinical Characteristics Associated With Lenvatinib-induced Fistula and Tumor-related Bleeding in Patients With Thyroid Cancer. Staub Y,Nishiyama A,Suga Y,Fujita M,Matsushita R,Yano S Anticancer research 39 7 3871 2019/07
  •  Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status Katsura H,Suga Y,Araya T,Kita T,Yoneda T,Tanaka N,Kawabata A,Ishita S,Mase H J. cancer 10 2139 2019
  •  Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database. Hideki Sugawara,Mayako Uchida,Shinya Suzuki,Yukio Suga,Yoshihiro Uesawa,Takayuki Nakagawa,Hisamitsu Takase Biological & pharmaceutical bulletin 42 7 1185 2019/05
  •  Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database. Yukio Suga,Mayako Uchida,Shinya Suzuki,Hideki Sugawara,Kazuhiro Torigoe,Akihiko Futamura,Yoshihiro Uesawa,Takayuki Nakagawa,Hisamitsu Takase Biological & pharmaceutical bulletin 42 5 801 2019
  •  Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study Shimokawa S,Sakata A,Suga Y,Isoda K,Itai S,Nagase K,Shimada T,Sai Y J. Pharm. Health Care Sci. 5 7 2019
  •  A nationwide survey of community pharmacist contributions to polypharmacy in opioid-using and non-using cancer patients in Japan. Suzuki S,Uchida M,Suga Y,Sugawara H,Kokubun H,Uesawa Y,Nakagawa T,Takase H Biological and Pharmaceutical Bulletin 2019
  •  Palonosetron on Days 1 and 5 versus Granisetron Daily (day 1–5) in Germ Cell Tumour Therapy Shimura Y,Izumi K,Itai S,Iwamoto H,Yaegashi H,Suga Y,Shimada T,Mizogami A,Sai Y In vivo 33 643 2019
  •  Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study Uda H,Suga Y,Toriba E,Staub AY,Shimada T,Sai Y,Kawahara M,Matsusita R 5 3 2019
  •  Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies Hashimoto S,Honda K,Fujita K,Miyachi Y,Isoda K,Misaka K,Suga Y,Kato S,Tsuchiya H,Kato Y,Okajima M,Taniguchi T,Shimada T,Sai Y J. Pharm. Health Care Sci. 4 27 2018
  •  Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods Suga Y,Ikeda N,Maeda M,Staub AY,Shimada T,Yonezawa M,Kitade H,Katsura H,Okada M,Ishizaki J,Sai Y,Matsushita R J. Pharm. Health Care Sci. 4 18 2018
  •  Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis Okada M,Fujii H,Suga Y,Morito S,Okada M,Nishigami J,Kawano M,Shimada T,Sai Y J. Pharm. Health Care Sci. 3 7 2017
  •  Co-administration of Dexamethasone Increases Severity and Accelerates Onset Day of Neutropenia in Bladder Cancer Patients on Methotrexate, Vinblastin, Adriamycin and Cisplatin Chemotherapy: A Retrospective Cohort Study Itai S,Suga Y,Hara Y,Izumi K,Maeda Y,Kitagawa Y,Ishizaki J,Shimada T,Mizokami A,Sai Y J. Pharm. Health Care Sci. 3 3 2017
  •  Change in Pharmacokinetics of Mycophenolic Acid as a Function of Age in Rats and Effect of Coadministered Amoxicillin/Clavulanate Junko Ishizaki,Tomoko Tsuda,Yukio Suga,Satsuki Ito,Kunizo Arai,Yoshimichi Sai,Ken-ichi Miyamoto BIOLOGICAL & PHARMACEUTICAL BULLETIN 35 7 1009 2012/07
  •  Evaluation of Selective Competitive Binding of Basic Drugs to alpha(1)-Acid Glycoprotein Variants Junko Ishizaki,Akiko Fukaishi,Chie Fukuwa,Satoko Yamazaki,Mayu Tabata,Takuya Ishida,Yukio Suga,Kunizo Arai,Koichi Yokogawa,Ken-ichi Miyamoto BIOLOGICAL & PHARMACEUTICAL BULLETIN 33 1 95 2010/01
  •  Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease Takami A,Mochizuki K,Okumura H,Ito S,Suga Y,Yamazaki H,Yamazaki M,Kondo Y,Asakura H,Nakao S Int. J. Hematol. 83 80 2006
  •  Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist Y Suga,H Asakura,T Yoshida,M Omote,Y Ontachi,T Mizutani,M Yamazaki,E Morishita,S Nakao,K Miyamoto BLOOD COAGULATION & FIBRINOLYSIS 15 7 593 2004/10
  •  Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats H Asakura,Y Suga,T Yoshida,Y Ontachi,T Mizutani,M Kato,T Ito,E Morishita,M Yamazaki,K Miyamoto,S Nakao BLOOD COAGULATION & FIBRINOLYSIS 14 3 221 2003/04
  •  Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models H Asakura,T Ichino,T Yoshida,Y Suga,Y Ontachi,T Mizutani,M Kato,T Ito,M Yamazaki,K Aoshima,E Morishita,M Saito,KI Miyamoto,S Nakao BLOOD COAGULATION & FIBRINOLYSIS 13 3 233 2002/04
  •  Marked difference in pathophysiology between tissue factor- and lipopolysaccharide-induced disseminated intravascular coagulation models in rats H Asakura,Y Suga,K Aoshima,Y Ontachi,T Mizutani,M Kato,M Saito,E Morishita,M Yamazaki,A Takami,K Miyamoto,S Nakao CRITICAL CARE MEDICINE 30 1 161 2002/01
  •  Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation H Asakura,Y Ontachi,T Mizutani,M Kato,T Ito,M Saito,E Morishita,M Yamazaki,K Aoshima,A Takami,T Yoshida,Y Suga,K Miyamoto,S Nakao EUROPEAN JOURNAL OF HAEMATOLOGY 67 3 170 2001/09
  •  All-trans retinoic acid is partially effective against lipopolysaccharide-induced but not against tissue-factor-induced disseminated intravascular coagulation in rat models H Asakura,K Aoshima,T Ichino,Y Suga,M Saito,E Morishita,M Yamazaki,Y Ontachi,T Mizutani,M Kato,KI Miyamoto,S Nakao BLOOD COAGULATION & FIBRINOLYSIS 12 4 301 2001/06
  •  Depressed plasma activity of plasminogen or alpha 2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation H Asakura,Y Ontachi,T Mizutani,M Kato,T Ito,M Saito,E Morishita,M Yamazaki,Y Suga,KI Miyamoto,S Nakao BLOOD COAGULATION & FIBRINOLYSIS 12 4 275 2001/06
  •  Beneficial effect of the active form of vitamin D-3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models H Asakura,K Aoshima,Y Suga,M Yamazaki,E Morishita,M Saito,K Miyamoto,S Nakao THROMBOSIS AND HAEMOSTASIS 85 2 287 2001/02
  •  Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases H Asakura,Y Ontachi,T Mizutani,M Kato,M Saito,E Morishita,M Yamazaki,Y Suga,A Takami,K Miyamoto,S Nakao BLOOD COAGULATION & FIBRINOLYSIS 12 1 1 2001/01

Conference Presentations

  • ヘパリン類・トラネキサム酸併用療法の終末期固形癌DICへの効果(conference:日本血栓止血学会誌)(2018/05)
  • 地域高齢者における薬剤使用実態とポリファーマシーの現状(conference:日本薬学会年会要旨集(CD-ROM))(2018/03)
  • 地域高齢者における認知機能と薬剤との関連性の検討:中島町研究(conference:医療薬学フォーラム講演要旨集)(2018/06)
  • 組織因子(TF)又はLipopolysaccharide(LPS)によるラットDICモデルの特徴と使い分けについて(conference:International Journal of Hematology)(1999/04)
  • LPS誘発DICモデルにおけるHMGB1の動態と低分子ヘパリンおよびrTMの影響(conference:日本血栓止血学会誌)(2006/10)

show all

  • 合成抗Xa薬(JTV803)及び低分子ヘパリン(LMWH)のラットDICモデルに対する効果(conference:International Journal of Hematology)(2000/04)
  • 造血幹細胞移植においてイトラコナゾールおよび主代謝物が血中シクロスポリン濃度に及ぼす影響(conference:日本薬学会年会要旨集)(2010/03/05)

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○2022「DICの多発血栓形成プロセスで鍵となる線溶病態の解明と新規治療戦略の提案」(2020-2022) 
○「がん薬物療法における血管痛発現機序の解明および新規予防法の開発」(2016-2019) 
○「肥満時の薬物動態変動による医薬品副作用の回避戦略」(2015-2018) 
○「抗癌剤による血管痛の誘発要因および予防策の基礎・臨床統合的検証」(2013-2015) 
○「基礎/臨床研究の融合による塩酸ゲムシタビン誘発性血管痛の最適な予防方法の構築」 
○「抗癌剤による嗅覚障害の実態とその早期発見による栄養状態の維持を指向した探索的研究」(2010-2011) 
○「組織因子またはLPS誘発ラットDICモデルの詳細な病態比較」(2005-2005) 

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Hospital Pharmacy Practice 1(2017)
○Presentation and Debate (Freshman Seminar II)(2017)
○Community Pharmacy Practice 2(2017)
○Community Pharmacy Practice 1(2017)
○Cancer Chemotherapy(2017)
○Hospital Pharmacy Practice 2(2017)
○Seminar in Drug Therapeutics(2017)
○Seminar in Pharmaceutical Practice(2017)
○Community Pharmacy Practice 1(2017)
○Community Pharmacy Practice 2(2017)
○Community Pharmacy Practice 1(2016)
○Hospital Pharmacy Practice 1(2016)
○Hospital Pharmacy Practice 2(2016)
○Community Pharmacy Practice 2(2016)
○Cancer Chemotherapy(2016)
○Seminar in Drug Therapeutics(2016)

Classes (Graduate Schools)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top